Comparative efficacy of the original and biosimilar eculizumab in the treatment of obstetric atypical hemolytic-uremic syndrome

Y.V. Korotchaeva, N.L. Kozlovskaya

Clinical pharmacology and therapy · 2021 · 10 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

Obstetric atypical hemolytic-uremic syndrome (aHUS) is an emergency with an unfavorable prognosis. The implementation of the complement-blocking drug Eculizumab into clinical practice significantly improved prognosis of patients with obstetric aHUS. In 2019, the first biosimilar of Eculizumab was developed in Russia by GENERIUM.

References

13